Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Myocarditis - Overview
Myocarditis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocarditis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocarditis - Companies Involved in Therapeutics Development
Apitope Intertiol NV
Cantargia AB
Cardiol Therapeutics Inc
CEL-SCI Corp
Evotec SE
Swedish Orphan Biovitrum AB
Myocarditis - Drug Profiles
akinra - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ATX-MYO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAN-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canbidiol 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Myocarditis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OBR-5340 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Peptides for Myocardial Infarction and Myocarditis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocarditis - Dormant Projects
Myocarditis - Product Development Milestones
Featured News & Press Releases
Dec 05, 2019: Cantargia selects CAN10 as development project in systemic sclerosis and myocarditis
Nov 25, 2019: Cardiol Therapeutics comments on the descheduling of Purisys Canbinoid ingredients by U.S. Drug Enforcement Agency
Nov 19, 2019: Cardiol Therapeutics announces clinical steering committee for phase 2 intertiol trial in Acute Myocarditis using CardiolRx 100
Oct 01, 2019: Cardiol Therapeutics announces completion of manufacturing scale-up for commercialization of CardiolRx 100
Jun 20, 2019: Cardiol Therapeutics announces plans for orphan drug program in acute myocarditis with CardiolRx CBD Formulation
Nov 22, 2018: LAB282: two years of drug discovery impact
Dec 11, 2017: Evotec’s Academic Bridge LAB282 with Oxford University celebrating one year of impact
Nov 10, 2016: Evotec and Oxford create novel Partnership called ’LAB282’
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Myocarditis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development for Myocarditis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Myocarditis - Pipeline by Apitope International NV, H1 2020
Myocarditis - Pipeline by Cantargia AB, H1 2020
Myocarditis - Pipeline by Cardiol Therapeutics Inc, H1 2020
Myocarditis - Pipeline by CEL-SCI Corp, H1 2020
Myocarditis - Pipeline by Evotec SE, H1 2020
Myocarditis - Pipeline by Swedish Orphan Biovitrum AB, H1 2020
Myocarditis - Dormant Projects, H1 2020